Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04674839
Other study ID # MS20CLIIS01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 18, 2019
Est. completion date November 20, 2020

Study information

Verified date December 2020
Source Microbio Co Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

MicrSoy-20 (MS-20), a fermented soymilk product, has been approved as an Over the counter (OTC) drug in 2011. The therapeutic effect of MS-20 is to ameliorate symptoms such as fatigue and loss of appetite caused by cancer chemotherapy. Animal study revealed orally administration of MS-20 daily for 4 weeks altered the gut microbiota composition in mice. In addition, MS-20 could activate dendritic cell and improve immunotherapy response rate. Thus, it was hypothesis that MS-20 improves host immune activity thus ameliorate fatigue and increase weight is through alteration the gut microbiota composition. In this study, the ability of MS-20 in modulating gut microbiota and the subset of microbiome to be altered by MS-20 was investigated.


Description:

This is a double-blind, placebo-controlled, investigator-initiated randomized trial to evaluate the impact of MS-20 on gut microbiota composition and abundance in healthy people. Approximately 100 subjects who meet the criteria of this study are planned to be enrolled. Eligible subjects will be randomized to receive placebo or MS-20 in a 1:1 ratio with 50 subjects in each arm. The study comprises of a 7 days screening period, a 8-week treatment period and a 8-week follow-up period. Eligible subjects will receive MS-20 or placebo every day during the treatment period. Participants should not use any probiotics and prebiotics during the trial. In addition, All medications (especially antibiotics) should be recorded and documented, however, fluoroquinolones and vancomycin will be banned during the trial. The fecal gut microbiota, serum, and urea were collect at indicated time. The gut microbiota composition, gut microbiota metabolite, and serum biochemical items will be analysed.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date November 20, 2020
Est. primary completion date September 4, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria: 1. Male or female subjects aged between 20 and 65 years old. 2. The subject is able to provide written informed consent by himself/herself and agrees to comply with all protocol requirements. 3. The subject agrees to comply with the following two requirements: 1. comply with all follow-up visit requirements according to the trial protocol. 2. comply with all requirement regarding fecal samples collection, storage and delivery according to the trial protocol. Exclusion Criteria: 1. The subject has soybean allergy. 2. The subject is pregnant or lactating. 3. The subject has received or is receiving chemotherapy. 4. The subject has received any antibiotic, antifungals or antivirals (excluding topical agents and antiviral prophylaxis for hepatitis B virus) within 30 days prior to visit 1 . 5. The subject has a clinically significant, currently active or underlying diarrhea (soft or loose stools more than three times in 24 hours) of infectious etiologies. 6. The subject has received any steroids, immunosuppressant or anti-inflammation drugs within 30 days prior to visit 1. 7. The subject has received probiotics or prebiotics 30 days prior to visit 1 8. The subject who has been diagnosed a chronic kidney disease, chronic gut inflammatory disease, cancer, or autoimmune disease within 1 year before participating this study. 9. Alcohol abuse, and smoking abuse. 10. The subject has active inflammatory bowel disease or gastric ulcer. 11. The subject currently is participating in studies involving other investigational drugs, medical devices, functional foods, or cosmetic. 12. The subject is considered by the investigator as not suitable for the trial. 13. The subject is judged by the investigator as not suitable for the trial due to concerns about possible non-compliance or severe concomitant illnesses.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
MS-20
fermented soymilk product
Other:
Placebo
No active ingredient

Locations

Country Name City State
Taiwan Microbio Group Taipei

Sponsors (1)

Lead Sponsor Collaborator
Microbio Co Ltd

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Gut microbiota from baseline to 8th week The composition, abundance and diversity of gut microbiota change from baseline in subjects treated with MS-20 or Placebo baseline to 8th week
See also
  Status Clinical Trial Phase
Withdrawn NCT03239197 - Project SHARE (motherS Have All the Right microbEs) N/A
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Recruiting NCT06144905 - Norwegian Microbiota Study in Anorexia Nervosa
Completed NCT05864352 - The Role of Dietary Titanium Dioxide on the Human Gut Microbiome and Health
Recruiting NCT04138979 - Intestinal Microbiota of Breast Cancer Patients Undergoing Chemotherapy
Recruiting NCT04132713 - Study on Skin Microbiome of HFS
Completed NCT05726435 - Effects of Soluble Dietary Fiber on Sport Efficiency and Fatigue Delay in Top Basketball Players N/A
Recruiting NCT02695784 - Probiotics After Discharge Phase 4
Completed NCT03543891 - Intestinal Microbiota and Thyroid Cancer
Completed NCT05242913 - Effects of Resistant Potato Starch on the Gut Microbiota N/A
Recruiting NCT04200521 - The Effect of Bariatric Procedures on Gut Microbiota in Obese Individuals in United Arab Emirates and Lebanon
Recruiting NCT05891977 - Effect of Tomato Paste Consumption on the Microbiota-gut-brain Axis in Healthy Adults N/A
Completed NCT02988349 - Ecological Effect of Arginine Dentifrice on Oral Microbiota N/A
Completed NCT05352724 - Clinical Trial to Evaluate the Efficacy of a Sport Drink After High-intensity Aerobic Exercise N/A
Completed NCT03754504 - Effects of Cranberry Powder Supplements on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT05394948 - Circular Economy and the Design of Healthy and Sustainable Food and Ingredients N/A
Terminated NCT03752372 - Microbiome Alterations in IL10RA-deficient Patients After HSCT
Completed NCT05974124 - Effectiveness of Ophthalmic Antiseptic Preparations N/A
Recruiting NCT02005003 - Cognitive and Metabolic Effects of a Probiotic Supplement N/A
Completed NCT04324749 - Healthy Prebiotic and Postbiotic Effects of Peanuts and Peanut Butter: College Intervention Trial N/A